GlaxoSmithKline (LON:GSK) Earns “Hold” Rating from Shore Capital

Shore Capital reiterated their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research note published on Wednesday morning, ThisIsMoney.Co.Uk reports.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group restated a buy rating and set a C$15.00 price objective on shares of Aphria in a research note on Friday, May 24th. Goldman Sachs Group set a $13.00 price objective on Ford Motor and gave the company a buy rating in a research note on Thursday, June 13th. Barclays raised their price objective on Intuit from $225.00 to $237.00 and gave the company an equal weight rating in a research note on Friday, May 24th. Deutsche Bank reiterated a buy rating and set a $80.00 target price on shares of Bayerische Motoren Werke in a research note on Monday, July 8th. Finally, UBS Group cut Telstra from a buy rating to a neutral rating in a research note on Monday, July 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. GlaxoSmithKline has a consensus rating of Hold and a consensus target price of GBX 1,535.88 ($20.07).

Shares of LON:GSK opened at GBX 1,623.80 ($21.22) on Wednesday. The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. The company’s fifty day moving average is GBX 1,584.74. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,651 ($21.57). The company has a market cap of $81.00 billion and a PE ratio of 20.69.

The company also recently disclosed a dividend, which was paid on Thursday, July 11th. Investors of record on Thursday, May 16th were issued a GBX 19 ($0.25) dividend. This represents a yield of 1.22%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 0.97%.

In other news, insider Manvinder Singh Banga acquired 458 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was bought at an average price of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). In the last three months, insiders purchased 482 shares of company stock valued at $755,935.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Story: LIBOR

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.